Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.600
+0.040 (2.56%)
At close: Jun 6, 2025, 4:00 PM
1.600
0.00 (0.02%)
After-hours: Jun 6, 2025, 7:51 PM EDT
Geron Revenue
Geron had revenue of $39.60M in the quarter ending March 31, 2025, with 12,927.30% growth. This brings the company's revenue in the last twelve months to $116.29M, up 22,264.04% year-over-year. In the year 2024, Geron had annual revenue of $76.99M with 32,386.92% growth.
Revenue (ttm)
$116.29M
Revenue Growth
+22,264.04%
P/S Ratio
9.10
Revenue / Employee
$507,830
Employees
229
Market Cap
1.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.99M | 76.76M | 32,386.92% |
Dec 31, 2023 | 237.00K | -359.00K | -60.23% |
Dec 31, 2022 | 596.00K | -797.00K | -57.21% |
Dec 31, 2021 | 1.39M | 1.14M | 450.59% |
Dec 31, 2020 | 253.00K | -207.00K | -45.00% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GERN News
- 4 days ago - Conservative Vision Of A Positive Future For Geron - Seeking Alpha
- 10 days ago - Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program - Business Wire
- 18 days ago - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade) - Seeking Alpha
- 4 weeks ago - GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm - Business Wire
- 4 weeks ago - Geron Corporation (GERN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN - GlobeNewsWire
- 4 weeks ago - Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire